Scopio’s technology utilizes Deep Learning AI technology and high-definition digital scans of blood samples in order to accurately analyze blood tests more efficiently.
Scopio Labs secured $50M in series C funding, which the company will use to scale manufacturing of its FDA-cleared imaging and AI analysis platform to support the shift to fully telehematology.